NuVasive's Attrax Putty was shown to be an effective bone graft substitute for autograft in instrumented thoracolumbar posterolateral lumbar fusion.
Four insights:
1. The Feb. 19 study published in Spine led the FDA to provide 510(k) clearance for expanded use of Attrax Putty without autograft.
2. Attrax Putty is a bioactive and osteoconductive bone void filler for the repair of bone defects, which provides an environment for bone formation without added cells or growth factors. The material is resorbed and replaced by bone during healing.
3. The study compared the fusion rates of the Attrax Putty with autograft in 100 patients across four hospital centers.
4. The fusion rates for the Attrax Putty and autograft were 55 percent and 52 percent respectively, with an overall fusion rate of 71 percent of levels.